

## Publications internationales AGIR 2018

**(P2018-01)** Comparison of Abbott Architect®, Siemens Immulite® and Diasorin Liaison® for determination of Epstein-Barr virus serological diagnosis

C. Francois, C. Segard, M. Bouvier, M. Stefanski, C. Pannier, P. Zawadzki, C. Roussel, D. Hecquet, G. Duverlie, E. Brochot, S. Castelain

*Diag. Microbiol. Inf. Dis.* 2018, 90(2), 96-101; doi: 10.1016/j.diagmicrobio.2017.10.020.

**(P2018-02)** Design, synthesis, and antiprotozoal evaluation of new 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline derivatives

J. Guillon, A. Cohen, R. Nath Das, C. Boudot, N. M. Gueddouda, S. Moreau, L. Ronga, S. Savrimoutou, L. Basmaciyan, C. Tisnerat, S. Mestanier, S. Rubio, S. Amaziane, A. Dassonville-Klimpt, N. Azas, B. Courtioux, J.-L. Mergny, C. Mullié, P. Sonnet

*Chem. Biol. Drug. Des.* 2018, 91(5), 974-995; doi.org/10.1111/cbdd.13164.

**(P2018-03)** Synthesis and antimalarial activity of new enantiopure aminoalcoholpyrrolo[1,2-a]quinoxalines

A. Jonet, J. Guillon, C. Mullié, A. Cohen, G. Bentzinger, S. Hutter, N. Azas, S. Moreau, S. Savrimoutou, P. Agnamey, A. Dassonville-Klimpt, P. Sonnet

*Med. Chem.* 2018, 14(3), 293-303; doi: 10.2174/1573406413666170726123938.

**(P2018-04)** Crystal structure of 2,8-bis(trifluoromethyl)-4-vinylquinoline

J. Guillon, A. Dassonville-Klimpt, S. Moreau, P. Laumaille, M. Marchivie, P. Sonnet

*X-ray Structure Analysis Online* 2018, 34, 15-16; doi.org/10.2116/xraystruct.34.15.

**(P2018-05)** Chemical composition of essential oil from *Atriplex lentiformis* leaves

O. Chouitah, B. Meddah, A. Aoues, P. Sonnet

*Chemistry of Natural compounds* 2018, 54(4), 772-773; doi 10.1007/s10600-018-2470-4.

**(P2018-06)** Intracranial suppurative complications of ear, nose and throat infections: A single-centre cohort study of 65 patients

M. Erlem, R. Guihéneuf, N. Klopp-Dutote, A. Biet-Hornstein, L. Dégrugilliers, C. Page

*Clin. Otolaryngol.* 2018, 43(3), 945-948; doi: 10.1111/coa.13071.

**(P2018-07)** Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus

C. Fournier, T.W. Hoffmann, V. Morel, V. Descamps, J. Dubuisson, E. Brochot, C. François, G. Duverlie, S. Castelain, F. Helle

*J. Viral Hepat.* 2018, 25, 63-71; doi.org/10.1111/jvh.12767.

**(P2018-08)** Hepatitis E virus lifecycle and identification of 3 forms of the ORF2 capsid protein

C. Montpellier, C. Wychowski, I. M. Sayed, J.-C. Meunier, J.-M. Saliou, M. Ankavay, A. Bull, A. Piliez, F. Abravanel, F. Helle, E. Brochot, H. Drobecq, R. Farhat, C.-M. Aliouat-Denis, J. G. Haddad, J. Izopet, P. Meuleman, A. Goffard, J. Dubuisson, L. Cocquerel

*Gastroenterology* 2018, 154(1), 211-223.e8; doi.org/10.1053/j.gastro.2017.09.020.

**(P2018-09)** Identification of piperazinylbenzenesulfonamides as new inhibitors of claudin-1 trafficking and Hepatitis C Virus entry

L. Riva, O. R. Song, J. Prentoe, F. Helle, L. L'homme, C. H. Gattoliat, A. Vandeputte, L. Fénéant, S. Belouzard, T. F. Baumert, T. Asselah, J. Bukh, P. Brodin, L. Cocquerel, Y. Rouillé, J. Dubuisson.  
*J. Virol.* 2018, 92(10), e01982-17; doi: 10.1128/JVI.01982-17.

**(P2018-10)** Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study)

J. Bulsei, S. Leroy, J.-M. Perotin, H. Mal, C.-H. Marquette, H. Dutau, A. Bourdin, J.-M. Vergnon, C. Pison, R. Kessler, V. Jounieaux, M. Salaün, A. Marceau, S. Dukic, C. Barbe, M. Bonnaire, G. Deslee, I. Durand-Zaleski

*Respir. Res.* 2018, 19(1), 84; doi: 10.1186/s12931-018-0796-x.

**(P2018-11)** Non-steroidal anti-inflammatory drug use and clinical outcomes of community-acquired pneumonia

D. Basille, R. W. Thomsen, M. Madsen, P. Duhaut, C. Andrejak, V. Jounieaux, H. T. Sørensen  
*Am. J. Respir. Crit. Care Med.* 2018, 198(1), 128-131; doi: 10.1164/rccm.201802-0229LE.

**(P2018-12)** Prospective observational study on the association between serum mannose-binding lectin levels and severe outcome in critically ill patients with pandemic *Influenza* Type A (H1N1) infection

E. Zogheib, R. Nyga, M. Cornu, B. Sendid, J. Monconduit, V. Jounieaux, J. Maizel, C. Segard, T. Chouaki, H. Dupont

*Lung* 2018, 196(1), 65-72; doi: 10.1007/s00408-017-0067-5.

**(P2018-13)** Functional study of the C-terminal part of hepatitis C virus E1 ectodomain

R. I. Moustafa, J. G. Haddad, L. Linna, X. Hanoulle, V. Descamps, A. A. Mesalam, T. F. Baumert, G. Duverlie, P. Meuleman, J. Dubuisson, M. Lavie

*J. Virol.* 2018, 92(20), e00939-18; doi: 10.1128/JVI.00939-18.

**(P2018-14)** Determinants of amikacin first peak concentration in critically ill patients

C. Boidin, S. Jenck, L. Bourguignon, S. Torkmani, A. Roussel, J. S. Ledochowski, L. Marry, N. Ammenouche, H. Dupont, F. Marçon, B. Allaouchiche, J. Bohé, A. Lepape, S. Goutelle, A. Friggeri  
*Fundam. Clin. Pharmacol.* 2018, 32(6), 669-677; doi: 10.1111/fcp.12374.

**(P2018-15)** Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin

F. Marçon, C. Guittet, M. A. Manso, I. Burton, L.-A. Granier, P. Jacqmin, H. Dupont  
*Eur. J. Pharm. Sci.* 2018, 114, 46-54; doi.org/10.1016/j.ejps.2017.11.030.

**(P2018-16)** Paediatric formulation: budesonide 0.1 mg/mL viscous oral solution for eosinophilic esophagitis using cyclodextrins

C. Ey, C. Hosselet, B. Villon, F. Marçon

*Pharm. Technol. Hosp. Pharm.* 2018, 3(2), 71-77; doi.org/10.1515/pthp-2018-0004.

**(P2018-17)** Epidemiology and seasonality of acute respiratory infections in hospitalized children over four consecutive years (2012-2016).

Fillatre, C. François, C. Segard, G. Duverlie, D. Hecquet, C. Pannier, C. Roussel, P. Zawadzki, E. Brochot, S. Castelain

*J. Clin. Virol.* 2018, 102, 27-31; doi.org/10.1016/j.jcv.2018.02.010.

**(P2018-18)** Late recurrence of an osteoarticular infection caused by *Klebsiella pneumoniae* in a child

I. Boulnois, R. Gouron, E. Pluquet, F. Peltier, M.C. Plancq, F. Deroussen, C. Klein

*Arch. Pediatr.* 2018, 25(8), 497-499; doi.org/10.1016/j.arcped.2018.09.009.

**(P2018-19)** Paediatric needs: challenge and opportunities for hospital pharmacists

F. Marçon

*Pharm. Technol. Hosp. Pharm.* 2018, 3(2), 47-48; doi.org/10.1515/pthp-2018-0016.

**(P2018-20)** Risk factors for BK virus viremia and nephropathy after kidney transplantation: A systematic review

B. Demey, C. Tinez, C. François, F. Helle, G. Choukroun, G. Duverlie, S. Castelain, E. Brochot

*Clin. Virol.* 2018, 109, 6-12; doi.org/10.1016/j.jcv.2018.10.002.

**(P2018-21)** Breastmilk donations: Bacteriological assessment, analysis of causes of non-compliance and suggestions for improvement

C. Mullié, O. Obin, G. Outurquin, S. Grognat, A. Léké, C. C. Adjidéa

*Arch. Pediatr.* 2018, 25(4), 263-268; doi.org/10.1016/j.arcped.2018.02.006.

**(P2018-22)** Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial

L. Mandelbrot, F. Kieffer, R. Sitta, H. Laurichesse-Delmas, N. Winer, L. Mesnard, A. Berrebi, G. Le Bouar, J.-P. Bory, A.-G. Cordie, Y. Ville, F. Perrotin, J.-M. Jouannic, F. Biquard, C. d'Ercole, V. Houfflin-Debarge, I. Villena, R. Thiébaut; TOXOGEST Study Group (member: A. Totet)

*Am. J. Obstet. Gynecol.* 2018, 219(4), 386.e1-386.e9; doi: 10.1016/j.ajog.2018.05.031.

**(P2018-23)** The fascinating echinocandin-treated mouse model of *Pneumocystis murina* to understand *Pneumocystis jirovecii*

G. Nevez, A. Totet, C. Damiani, S. Le Gal

*Antimicrob. Agents Chemother.* 2018, 62(8), e00992-18; doi: 10.1128/AAC.00992-18.